ecancermedicalscience

Short Communication

WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results

3 Dec 2015
Felipe Ades, Nise Yamaguchi

In recent years, with the rise of immunotherapeutic agents for cancer treatment, we have observed a paradigm shift in oncology drug development. One common problem accompanying such paradigm shifts is how to build research strategies to fit the mechanism of action of the newer compounds. Developing immunotherapy in oncology requires us to address the unique characteristics of immunotherapeutic agents and to provide adequate tools for their evaluation, including the adjustment of clinical trial endpoints. Immunotherapy creates patterns of response different from those of chemotherapy, and thus they are not captured by the traditional World Health Organisation (WHO) tumour response criteria or the RECIST. Revisiting the results of pembrolizumab in patients with melanoma can help to evaluate the efficacy of the immune-related response criteria (irRC) as the gold standard for evaluating the clinical response of immunologic agents in oncology.

Related Articles

Solomon Kibudde, Awusi Kavuma, Bonny Abal, Moses Fredrick Katumba, Cissy Bangidde Namutale, Daniel Kanyike, Israel Luutu
Elias Zonana-Schatz, Jenniffer Ann-Swain, Jenny Naomi Shiraishi-Piña, Marcos Cherem-Kibrit, José Rodrigo Espinosa
Swasthik Upadhya, Sameer Rastogi, Adarsh Barwad, Shamim Ahmed Shamim, Dikhra Khan, Sudheer Arava, Vineeta Ojha, Akshit Kumar Ganesan Karthikeyan, Akshya Kumar Bisoi
Miguel Araujo-Meléndez, Mirza Jacqueline Alcalde-Castro, Andrea De-la-O-Murillo, Thierry Hernandez-Gilsoul, Enrique Soto-Perez-de-Celis, Roberto Gonzalez-Salazar, Yanin Chavarri-Guerra